Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C

Ann Oncol. 2024 Mar;35(3):328-329. doi: 10.1016/j.annonc.2023.11.012. Epub 2023 Nov 28.
No abstract available

Publication types

  • Letter

MeSH terms

  • Acrylamides*
  • Aniline Compounds / therapeutic use
  • Antibodies, Bispecific*
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Disease Progression
  • ErbB Receptors / genetics
  • Humans
  • Indoles*
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Morpholines*
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles*
  • Pyrimidines*

Substances

  • osimertinib
  • lazertinib
  • amivantamab-vmjw
  • Aniline Compounds
  • ErbB Receptors
  • Protein Kinase Inhibitors
  • EGFR protein, human
  • Antibodies, Bispecific
  • Morpholines
  • Acrylamides
  • Pyrimidines
  • Indoles
  • Pyrazoles